CEL-SCI Corporation (CVM)
| Market Cap | 17.39M +39.9% |
| Revenue (ttm) | n/a |
| Net Income | -22.70M |
| EPS | -3.32 |
| Shares Out | 17.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,547 |
| Open | 1.0000 |
| Previous Close | 0.9744 |
| Day's Range | 0.9900 - 1.0300 |
| 52-Week Range | 0.8900 - 13.4770 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections,... [Read more]
Financial Performance
Financial StatementsNews
CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026
CEL-SCI (CVM) announced the successful conclusion of a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 on June 22nd in San Diego. Under the agreement, Amarox…
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.
CEL-SCI Announces Closing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.
CEL-SCI highlights dual-track strategy for Multikine
CEL-SCI (CVM) highlighted its dual-track strategy to bring Multikine to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saud...
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.
CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
CEL-SCI, Saudi Amarox to conduct signing ceremony for strategic agreement
CEL-SCI (CVM) Corporation announced it will participate in a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego, California. The ceremony will mark a…
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.
CEL-SCI reports Q2 EPS (67c) vs. ($2.33) last year
“During the fiscal second quarter, we made significant progress advancing Multikine toward potential commercialization and regulatory approval in multiple markets,” stated CEL-SCI (CVM) CEO Geert Kers...
CEL-SCI Reports Fiscal Second Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.
CEL-SCI 6M share Secondary priced at $1.20
ThinkEquity acted as sole book running manager for the offering.
CEL-SCI Corporation Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.
CEL-SCI enters strategic agreement with Amarox over Multikine distribution
CEL-SCI (CVM) announced it has signed a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine in...
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.
CEL-SCI files to sell 3.44M shares of common stock
ThinkEquity is acting as the exclusive placement agent in connection with this offering.
CEL-SCI Reports Fiscal First Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.
CEL-SCI Reports Fiscal 2025 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.
CEL-SCI files to sell 375,000 shares of common stock for holders
16:32 EST CEL-SCI (CVM) files to sell 375,000 shares of common stock for holders
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executiv...
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Off...
CEL-SCI Announces Closing of $10 Million Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $10 million public offering.
CEL-SCI 1.11M share Spot Secondary priced at $9.00
The deal priced below last closing price of $13.04. ThinkEquity is acting as sole book running manager for the offering.
CEL-SCI Announces Pricing of $10 Million Public Offering
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $10 million public offering.
CEL-SCI announces common stock offering, no amount given
CEL-SCI (CVM) announced that it intends to offer to sell shares of its common stock in a best-efforts public offering. All of the shares of common stock are being offered…